This trial will compare the effectiveness of two different treatments for breast cancer. One treatment will be Fulvestrant plus Enza, and the other will be Fulvestrant by itself. The trial will last for four months, and will involve postmenopausal women with locally advanced breast cancer.
1 Primary · 4 Secondary · Reporting Duration: 16 weeks
61 Total Participants · 2 Treatment Groups
Primary Treatment: Fulvestrant · Has Placebo Group · Phase 2
Age 18 - 101 · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: